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Ion pumps as biological targets for decavanadate
Manuel Aureliano,*a,b Gil Fraquezab,c and C. André Ohlind
The putative applications of poly-, oligo- and mono-oxometalates in biochemistry, biology, pharmacology
and medicine are rapidly attracting interest. In particular, these compounds may act as potent ion pump
inhibitors and have the potential to play a role in the treatment of e.g. ulcers, cancer and ischemic heart
disease. However, the mechanism of action is not completely understood in most cases, and even remains
largely unknown in other cases. In the present review we discuss the most recent insights into the inter-
action between mono- and polyoxometalate ions with ion pumps, with particular focus on the interaction
of decavanadate with Ca2+-ATPase. We also compare the proposed mode of action with those of established
ion pump inhibitors which are currently in therapeutic use. Of the 18 classes of compounds which are
known to act as ion pump inhibitors, the complete mechanism of inhibition is only known for a handful. It
has, however, been established that most ion pump inhibitors bind mainly to the E2 ion pump conformation
within the membrane domain from the extracellular side and block the cation release. Polyoxometalates
such as decavanadate, in contrast, interact with Ca2+-ATPase near the nucleotide binding site domain or at a
pocket involving several cytoplasmic domains, and therefore need to cross through the membrane bilayer.
In contrast to monomeric vanadate, which only binds to the E2 conformation, decavanadate binds to all
protein conformations, i.e. E1, E1P, E2 and E2P. Moreover, the speciﬁc interaction of decavanadate with sarco-
plasmic reticulum Ca2+-ATPase has been shown to be non-competitive with respect to ATP and induces
protein cysteine oxidation with concomitant vanadium reduction which might explain the high inhibitory
capacity of V10 (IC50 = 15 μM) which is quite similar to the majority of the established therapeutic drugs.
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1. Introduction
The serendipitous discovery three decades ago of vanadium as
an inhibitor of ion pumps such as Na+/K+-ATPase (IC50 = 40
nM)1 has encouraged the investigation of mono and polyoxo-
metalates as putative drugs in the treatment of several diseases
in which the molecular target has been established to be an
ion pump such as Na+/K+-ATPase, H+/K+-ATPase, or Ca2+-
ATPase.2 These enzymes are all classified as P-type, or E1-E2,
ATPases, in which the ion pump process is coupled to ATP
hydrolysis. The mechanism is well-known and involves at least
four steps and two distinct protein conformations, E1 and E2.3
These conformations are usually highly selective towards
specific substrates, where the E1 state has a greater aﬃnity for
the exported ion and ATP, and a low aﬃnity for the imported
ion, while the E2 conformation has a higher aﬃnity for the
imported ion and a low aﬃnity for the exported ion, thus
releasing it into the extracellular environment. ATP provides
the driving force in this process, by inducing the structural
changes through the phosphorylation of an aspartate residue.
The E1–E2 cycle consists of four steps. For instance, in the
process of calcium transport across the membrane, the E2
form of the calcium ATPase binds two calcium ions, thus
forming the E1 conformation. This conformation is phos-
phorylated by ATP forming an E1P intermediate, where the P
indicates that the enzyme is phosphorylated, which leads to
ion translocation and release of the calcium. This is followed
by the formation of the calcium-free proton-carrying E2P con-
formation which undergoes hydrolysis of the phosphate–aspar-
tate bond to regenerate E2 and release the protons, and the
cycle is complete.3 It is in fact the phosphorylation step that
gives the P-type ATPases their name, and they present a
common target for inhibitors which can interfere with this
particular step.
In terms of structural features these P-type ATPases each
possess a nucleotide binding domain and a phosphorylation
binding site on the cytoplasmic side, and a cation binding site
located inside the membrane region.3,4 These three distinct
domains (Fig. 1) can all serve as potential targets for diﬀerent
types of E1–E2 ATPase inhibitors.
A range of established drugs, such as ouabain, omeprazole
and thapsigargin, are known to act as ion pump inhibitors,
but the mechanism and protein binding sites, or even main
target enzyme, have only been clearly established for a few of
these compounds (described in Tables 1–3).2 For example, the
cardiotonic steroids (CTS) mainly inhibit Na+/K+-ATPase,
whereas the proton pump inhibitors (PPI) and potassium
blockers (also known as potassium competitive acid blockers;
PCAB) are named for their inhibition of H+/K+-ATPase. Thapsi-
gargin (TG) and cyclopiazonic acid (CPA) are examples of Ca2+-
ATPase inhibitors.
The principal role of the sarcoplasmic reticulum (SR) Ca2+-
ATPase is to remove cellular Ca2+ from the cytoplasm to the
SR, which it does as part of the process of muscle relaxation.
In addition, SR Ca2+-ATPase is an important actor in the
process of calcium homeostasis.3,5 This makes it a particularly
attractive target as it may play important roles in the control of
heart disease and cancer.
It is well-established that the process of calcium transport
and ATP hydrolysis can be inhibited by monomeric vanadate
(V1), VO4
3−, particularly under conditions where the E2 confor-
mation is favoured, leading to the formation of a conformer
analogous to E2P, but involving vanadate instead of phos-
phate.6,7 Therefore, the vanadate mode of action may involve
formation of an E2V analogue after condensation of vanadate
to the enzyme phosphorylation site, at aspartate residue 351.
Analysis of the E2 conformation clearly shows structural
changes relative to conformation E1 (Fig. 1). In particular, the
phosphorylation site is now sterically hindered.2,4
This is not very surprising given the similarities and diﬀer-
ences between the aqueous chemistry phosphorous and
vanadium, which may help explain some of the observed toxi-
city of the latter, in particular compared with other group 5
and 6 metals. In particular, both vanadate and phosphateDr C. André Ohlin
Dr C. André Ohlin is an Australian
Research Council-funded senior
research fellow at Monash Univer-
sity in Australia. His research
interests include the reaction
dynamics of polyoxometalates by
NMR and mass spectrometry, and
the catalytic activation of small
molecules by metal oxide
complexes.
Fig. 1 Schematic view of the E1 form of Ca2+ SR ATPase. Note the two calcium
ions (purple) in the cation channel.4 Figure based on RCSB deposition 1KJU.
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readily form linear oligomers in the tetrahedral state, in con-
trast with e.g. molybdate and tungstate. However, conden-
sation occurs spontaneously for vanadates in acidic solution
and has several easily accessible oxidation states, whereas
phosphate condensation is thermally driven in the solid phase
and phosphorous is most likely to be found in the +V state
Table 1 IC50 values and/or dissociation constants and therapeutical applications of known Na
+/K+-ATPase inhibitors
Class of inhibitor Compounds IC50 [μM] Kd [nM] Therapeutical applications References
Na+/K+-ATPase inhibitors
Cardiotonic steroids Ouabain >10 Treatment of congestive heart
failure and cardiac arrhythmia
10
0.01–0.5 10
0.600 11
2.2 12
0.08–0.32 12
1.8 13
1–100 14
60 15
27.7 16
28 3.62 16
1 17
Dihydro-ouabain >1000 15
Digoxin 0.910 11
20 15
Digoxigenin >100 15
Strophanthidin 160 15
Ouabagenin >1000 15
Chlorpromazine Chlorpromazine (CPZ) Kd1 = 32 500 Phototoxic antipsychotic drug 18
Kd2 = 142 500 18
62.5 20
Chloroquine Chloroquine (CLQ) Kd1 = 20 000 Anti-malarial drug 18
Kd2 = 115 000 18
Procaine and derivatives Procaine 17 700 Local anesthetics 20
Chloroprocaine 13 000 20
Bupivacaine 6700 20
Mepivacaine >10 000 20
Lidocaine 30 400 20
Palytoxin 0.8 Tumor promoter 12
Palytoxin (PTX) 0.2–0.45 12
0.0035 16
0.4–3.1 20 000 21–23
Gramicidin A Gramicidin A 8.1 Antibiotic 24
Tungsten compounds (W12) 12-tungstosilicic acid
H4SiW12O40 (WSiA)
3.4–4.3 Insulin-mimetic properties 25
(W12) 12-tungstophosphoric acid,
H3PW12O40 (WPA)
2.9–3.1 25
(W1) sodium tungstate 1300–1500 25
Table 2 IC50 values and/or dissociation constants and therapeutical applications of known H
+/K+-ATPase inhibitors
Class of inhibitor Compounds IC50 [μM] Kd [nM]
Therapeutical
applications References
H+,K+-ATPase inhibitors
PPIs (proton pump inhibitors) Omeprazole 30 Anti-ulcer agents
(duodenal and gastric)
26
50 27
2.4 28
3.9 29
36 29
Pantoprazole 6.8 28
PCABs (potassium-competitive acid
pump antagonists, formerly APA)
SCH 28080 (2-methyl-
8-(phenylmethoxy)imidazo[1,2-a]-
pyridine-3-acetonitrile)
14.3 Anti-ulcer agents 30
Soraprazan 0.1 26.4 31
Diterpenoids Scopadulcic acid B (SA-B) 54 Antiviral agent 32
20–30 33
Diacetyl scopadol (DAS) 17 32
Prodigiosins Prodigiosin 25-C 0.03 Antibiotic 34
Prodigiosin 1.5 26
Metacycloprodigiosin 3.0 26
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under physiological conditions. There is also no shortage of
polyoxovanadates consisting of octahedral building blocks
while phosphates typically are found as tetrahedral units. In
addition, vanadium is considerably more electrophilic than
phosphorous and V–O bonds are less covalent than P–O bonds.
The situation is, however, rendered more complex by the
availability of three distinct binding domains in the P-ATPases,
only one of which is involved in the phosphorylation step. For
example, decavanadate (V10), [V10O28]
6−, is a more potent SR
Ca2+-ATPase inhibitor than monomeric vanadate6,8 and inter-
acts with other conformations besides E2. In this case the
binding site is not the same as the ATP binding site.8 More-
over, recently it was shown that during the mechanism of deca-
vanadate-mediated SR Ca2+-ATPase inhibition, a protein
cysteine unit is oxidized through reduction of the vanadate,
although the full implications of this process are not yet
clear.9 Therefore, a better understanding of the mechanism of
decavanadate calcium pump inhibition will help in evaluating
the potential of other members of the rich polyoxometalate
family as therapeutic agents for a range of diseases.
In this Perspective we aim to analyse and compare several
ion pump inhibitors, their putative mode of action and
protein binding sites, with particular focus on the role of
vanadium and other transition metal oxide ions. The majority
of these ion pump inhibitors are in current use as thera-
peutic drugs and we compare their inhibitory capacity with
mono- and polyoxometalates, which have activities of similar
magnitude.
Decavanadate has already been established as a potent ion
pump inhibitor and has several attractive properties. It is a
non-competitive inhibitor with respect to ATP, it has a high
inhibitory capacity (IC50 = 15 μM), and it is not selective
towards a specific protein interaction and can interact with the
calcium-induced E1 conformation rather than just the E2 con-
formation. V10 also binds to a cytoplasmic pocket involving
several domains and it induces cysteine oxidation and
vanadium reduction to yield V(IV) species. In contrast, the
majority of the established drugs bind to the protein only from
the extracellular side within the membrane domain, and block
the cation release, without interfering with the nucleotide
binding site.
2. Na+/K+-ATPase inhibitors
Na+/K+-ATPase is a target in the treatment of a wide range of
conditions, and inhibitors of this target include compounds
used to treat diseases such as heart failure, psychosis and
malaria. In addition, this pump is also a target for anae-
sthetics, antibiotics and insulin mimetic agents (Table 1).
Cardiotonic steroids such as ouabain are strong inhibitors
of Na+/K+-ATPase, with IC50 values below 1 μM (Table 1).
Ouabain inhibits the pump through binding to the extracellu-
lar domain of the pump near the cation entrance site when
the pump is in the E2P conformation, thereby inducing an
increase of intracellular Na+ concentration that leads to an
Table 3 IC50 values and/or dissociation constants and therapeutical applications of known Ca
2+-ATPase (SERCA) inhibitors
Class of inhibitor Compounds
IC50
[μM] Kd [nM] Therapeutical applications References
SERCA inhibitors
Thapsigargin Thapsigargin (TG) 0.029 Prodrugs for prostate cancer therapy 35
0.001 36,37
0.01674 38
Cyclopiazonic acid Cyclopiazonic acid (CPA) 7 Cardioprotective action in myocardial
ischemia
39
0.2 40
1.0 40
3.0 36
Macrocyclic lactones Cyclosporin A 62 Immunosuppressant agent,
antihelminthic agent (ivermectin)
41
Ivermectin 3.54 42
14.9 41
Rapamycin 77 41
Curcuminoids Curcumin 15.0 Antitumoral, anti-oxidant,
antiarthritic, antiamyloid and
anti-inflammatory agents
43
7.0–17.0 Kd1 = 550 44
Kd2 = 10 000 44
2,5-Di-(t-butyl)-
dihydroxybenzene
BHQ 200 Anti-oxidant agent 45
Celecoxib Celecoxib 35 Anti-inflammatory drug 46
35 35
Vanadium
compounds
Vanadate monomeric (V1) 50 Insulin-mimetic properties 8
Decavanadate (V10) 15 1000 8
PDC-V(V) – pyridine-2,6-
dicarboxylatodioxovanadium(V)
25 47
BMOV – bis(maltolato)oxovanadium(IV) 40 47
Vanadate (V1) 80 47
HAIDA-V(IV) – bis(N-
hydroxylamidoiminodiacetato)-
vanadium(IV)
325 47
Tungsten compounds (W1) sodium tungstate 400 8
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increase of intracellular calcium concentration through the
Na+/Ca2+ exchanger. This in turn leads to an increase in
muscle contraction which is the origin of the classification of
ouabain as a cardiotonic drug. That it is also being used in the
treatment of breast cancer emphasises the importance of the
ion pumps in the regulation of calcium homeostasis and cell
survival.10–17 It is not clear if diﬀerent-sized CTS also bind to
the same site or as strongly, and whether they block the trans-
location of intracellular sodium with the same potency.2
Other Na+/K+-ATPase inhibitors include the anti-psychotic
drug chlorpromazine, the anti-malarial agent chloroquine and
the antibiotic gramicidine A (IC50 = 8 μM) (Table 1).10–25
These drugs also aﬀect other proteins, however, and the
eﬀects on the Na+/K+-ATPase are only observed for higher
concentrations.18,19
Monomeric vanadate is a well-known Na+/K+-ATPase inhibi-
tor which is selective towards the E2P conformation. Besides
vanadate, tungstate also is known to inhibit the Na+/K+-
ATPase, with dodecatungstate (W12) exhibiting a higher
capacity of inhibition (IC50 ca. 3 μM) than the tungstate ion,
WO4
2− (IC50 = 1.5 mM).
25 However, monomeric tungstate has
been demonstrated to be a more potent inhibitor than dodeca-
tungstate towards SR Ca2+-ATPase (IC50 = 400 μM).8 Moreover,
it has been suggested that for Na+/K+-ATPase tungstate pre-
sents a competitive type of inhibition towards ATP, and blocks
the enzyme at the nucleotide domain.8
3. H+/K+-ATPase inhibitors
H+/K+-ATPase inhibitors include anti-ulceral, anti-viral and
antibiotic agents (Table 2). H+/K+-inhibition is normally a strat-
egy in preventing acidic segregation since gastric diseases are
very painful and can lead to hepatic ulceration. Proton pump
inhibitors (PPI), such as the drug omeprazole (IC50 ca.
3–4 μM), present lower inhibitory capacity than the potassium
competitive acid blockers (PCAB; IC50 = 0.1 μM) or prodigiosin
(IC50 = 0.03 μM).26–34
Omeprazole irreversibly inhibits H+/K+-ATPase through the
formation of a metabolite which reacts with the cysteine resi-
dues of the protein and causes pump inhibition. It was shown
that cysteine residue 813 is oxidized upon PPI interaction, but
other cysteine residues may also be involved such as cysteine
residues 321, 822 or 892, which are part of several trans-
membranal helices.
Vanadate is shown to be a potent H+/K+-ATPase inhibitor as
it is for the Na+/K+-ATPase.62 It reacts with the E2 form of the
enzyme and when the E1 form is favoured the inhibition was
not observed.63
4. Ca2+-ATPase inhibitors
The Ca2+-ATPase inhibitors include compounds used for
cancer therapy, cardioprotection, immunosuppression and as
antitumoral agents (Table 3). Thapsigargin (TG) is currently
the most potent calcium pump inhibitor known, and presents
an inhibitory value in the nM range (IC50 = 1 nM)
8,35,45–47
(Table 3). The inhibition leads to increasing cytoplasmic
calcium levels, which leads to the activation of apoptotic
factors which trigger cell death, making TG an active anti-
tumoral agent.
Both TG and cyclopiazonic acid (CPA; IC50 ca. 1 μM) bind to
the E2 conformation of the enzyme, but at diﬀerent binding
sites.2 As described for other P-type inhibitors, these com-
pounds bind to the protein in the membrane domain, at the
entrance of the calcium release channel close to the mem-
brane surface. However, TG and CPA do not bind to the same
exact site, and therefore the protein can bind simultaneously
to both inhibitors.2 Benzohydroquinone (BHQ) inhibitors bind
to the same binding site as CPA.
Whereas TG blocks the transmembranal helices TM3, TM5
and TM7, CPA moves TM1, TM2 towards to TM4. In both types
of interaction the drugs prevent the release of calcium.
Although the majority of the Ca2+-ATPase inhibitors in Table 3
seem to block the E2 conformation of the enzyme, a few, such
as curcumine, also interact with the E1P conformation.2
Vanadate species, in particular decavanadate (V10), are
potent inhibitors (IC50 = 15 μM) of the hydrolytic activity of the
sarcoplasmic reticulum Ca2+-ATPase, with activities similar to
that observed for decaniobate, [Nb10O28]
6−, and higher than
for WO4
2− and MO4
2−.8 SR Ca2+-ATPase activity is also inhi-
bited by vanadium complexes such as vanadium-citrate and
bis(maltolato)oxovanadium(IV) (BMOV) (Table 1).47,48 These
and other vanadium compounds have been described in the
treatment of diabetes mellitus.49 Furthermore, decavanadate,50
and compounds containing decavanadate51 have been
reported to lower glycemic levels,50,51 and to normalize plasma
lipid profiles.51
Due to the ability of V10 to interfere with several biological
processes, such as calcium homeostasis, muscle contraction
and oxidative stress,8,54,55 not only in vitro but also in vivo,52,53
decavanadate has recently been associated with the treatment
of Leishmaniosis.56 In this and probably in many other cases
the mechanism of action of decavanadate progresses via the
inhibition of the E1–E2 Ca2+-ATPases. However, mitochondria
may be an additional target as several mitochondrial processes
have been shown to be aﬀected by decavanadate at nanomolar
concentrations.57,58
Decavanadate can also induce protein cysteine oxidation
with concomitant V(V) reduction to V(IV). Thus we cannot
exclude the potential activity of V(IV) species in inducing
changes in the Ca2+-ATPase structure and function.8,9 Both
decaniobate and decavanadate have recently been shown to
interact non-competitively with SR Ca2+-ATPases with respect
to ATP. The V10 binding site on the E2 conformer is located at
the intersection of the three cytoplasmic protein domains that
includes the nucleotide, the phosphorylation and the β-strand
domains.4 Twenty years ago decavanadate was demonstrated
to be specific in inducing crystallization of SR Ca2+-ATPase.59
These and other recent studies emphasize that decavanadate
interactions with the calcium pump are clearly diﬀerent from
Dalton Transactions Perspective
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those of monomeric vanadate by inducing diﬀerent changes in
protein structure and function, and indicate diﬀerent biologi-
cal roles for the two oxovanadate species. These diﬀerences
may explain the diﬀerent biological eﬀects described in several
studies. For instance, at near-physiological conditions with
calcium and without a calcium ionophore only decavanadate
inhibits calcium translocation whereas vanadate does not.6
Still, although there has been some progress in improving the
understanding of the interaction and the eﬀect of V10 on the
structure and function of the Ca2+-ATPases, the mechanism of
action on the Ca2+-ATPase is still not fully understood, parti-
cularly under physiological conditions.
Given that the decavanadate-specific Ca2+-ATPase binding
site is located on the cytoplasmic side, one would expect that
V10 needs to cross the cell membrane in order to be active.
Decavanadate can, however, also aﬀect the cell membrane
itself,60 for example by decreasing lipid packing which may
induce changes in the composition of proteins in membrane
microdomains.61 This oﬀers an indirect mode of action which
does not require transmembranal transport. By changing
membrane structure and dynamics, alterations on the struc-
ture and function of the E1–E2 ATPases can also occur. Finally,
we cannot exclude that V10 might interact with the ion pumps
from the extracellular space, as is the case with many drugs
(Fig. 1).
Polyoxotungstates have also been shown to inhibit not only
ion pumps such as Na+/K+-ATPase, H+/K+-ATPase, and Ca2+-
ATPase but also ecto-ATPases.25 In fact, polyoxotungstates are
10–100 times more potent as inhibitors25 than monovanadium
coordination complexes,47,48 while decavanadate IC50 values
are one to two orders of magnitude lower than those of the
polyoxotungstates.8,9
The mechanism of inhibition and interaction of decavana-
date on the sarcoplasmic reticulum calcium pump ATPase is
clearly diﬀerent from that of other polyoxometalates and oxo-
metalates. It involves protein cysteine oxidation and vanadate
reduction processes, which lead to non-competitive ATPase
inhibition. This inhibition is not prevented by antioxidant
agents that can reverse the cysteine oxidation.9 Moreover, deca-
vanadate interacts with ATPase in the same fashion for all the
conformations that occurs during the ATP-hydrolysis coupled
calcium translocation. These recent findings emphasise the
crucial need to properly understand and compare the ion
pump inhibition processes of several types of inhibitors, since
they may well turn out to be significantly diﬀerent.
Given the specific activity of these structures towards the
ion pumps, polyoxometalates are promising as drugs for anti-
cancer activity, protection against viral, bacterial and protozoa
infections, and antidiabetic activity.49–51,56
5. Conclusions
Although some 18 classes of ion pump inhibitors are known,
the biochemical mechanisms are only known for a handful of
compounds. The majority of these compounds – such as
ouabain, omeprazole, thapsigargin, CPA and BHQ – seem to
interact selectively with the E2 or E2P conformations of the
target enzyme, which can be understood in light of the
binding site being located in the transmembranal region, at or
close to the calcium binding site. The binding is normally
reversible, but, in the case of omeprazole, nearby cysteine
units are also directly aﬀected, which leads to the irreversible
inhibition of the pump.
Thapsigargin is one of the most potent inhibitors of the
Ca2+-ATPases, and of all the E1–E2 ion pump inhibitors dis-
cussed in the present Perspective, with an IC50 in the nM
range of concentration. While vanadium and tungsten mono-
and polyoxometalates have IC50 values which are three orders
of magnitude (IC50 = 2–15 μM) higher than TG, they still have
activities comparable with other relevant ion pump inhibitors.
The mode of action of decavanadate and the other oxometa-
lates implies that the main focus of the interaction is on the
cytoplasmic domain of the protein, more specifically at the
nucleotide or phosphorylation domains or at a pocket invol-
ving several cytoplasmic domains. Although decavanadate
interacts most strongly with the E2 conformation of the Ca2+-
ATPase, as do some of the other drugs described above, deca-
vanadate also interacts with other conformations.6,8 Therefore,
decavanadate exhibits a particular feature that may be useful
for the understanding of the mode of action of ion pump
inhibitors in general. Besides, the specific behaviour of decava-
nadate towards ion pumps may guide the development of new
drugs that would have these pumps as therapeutic targets.
Finally, it is believed that the present observations will contri-
bute to the understanding of oxometalate interactions with the
Fig. 2 E1–E2 ATPases, a family of cation pump enzymes, are known targets for
speciﬁc drugs including decavanadate (V10). The majority of the drugs bind
within the bilayer near the entrance of the cation exit channel whereas decava-
nadate binds to a pocket formed by protein domains at the cytoplasmic side.
Decavanadate and other polyoxometalates need to cross the bilayer before tar-
geting the ion pumps, something which probably occurs through transport
membrane systems such as channels, or speciﬁc transporters and/or pumps. In
contrast, established organic drugs do not apparently need to cross the mem-
brane, and probably for V10 this mechanism of action cannot be completely
excluded. Na+/K+, H+/K+, and Ca2+ stand for Na+, K+-ATPase, H+, K+-ATPase, and
Ca2+-ATPase, respectively. SR denotes sarcoplasmic reticulum.
Perspective Dalton Transactions
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calcium pump and the role of decavanadate in biology,
particularly the contribution of decavanadate to calcium
homeostasis.
In summary, E1–E2 ATPases are targets for several classes
of compounds, including decavanadate, and present several
potential binding sites. The majority of the established drugs
bind near the entrance of the cation binding sites within the
bilayer, whereas decavanadate binds to a pocket formed by
protein domains at the cytoplasmic side. Decavanadate and
other polyoxometalates need to cross the bilayer before target-
ing the ion pumps, something which probably occurs through
transport membrane systems such as channels, or specific
transporters and/or pumps. In contrast, a majority of estab-
lished organic drugs do not appear to need to cross the mem-
brane. However, the former mechanism of action cannot be
completely excluded for decavanadate (Fig. 2).
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